| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-10- | 832145 | 恒合股份 | 14914315.0 | 17317.78 | 异常期间涨跌幅偏离值累计 | | 29 | | | | | 达到64.32% | | 2024-10- | 832802 | 保丽洁 | 14805601.0 | 29881.96 | 异常期间涨跌幅偏离值累计 | | 29 | | | | | 达到64.31% | | 2024-10- | 831856 | 浩淼科技 | 26385668.0 | 27078.24 | 异常期间涨跌幅偏离值累计 | | 29 | | | | | 达到64.24% | | 2024-10- 29 | 830964 | 润农节水 | 5221223 | 3431.3 | 异常期间涨跌幅偏离值累计 达到64.13% | | 2024-10- | | | | | 异常期间涨跌幅偏离值累计 | | 29 | 872392 | 佳合科技 | 15804573.0 | 3 ...

证券代码：839273 证券简称:一致魔芋 公告编号：2024-098 湖北一致魔芋生物科技股份有限公司股票交易异常波动公告 （2）是否存在可能或已经对本公司股票交易价格产生较大影响的媒体报道或市场传闻， 是否涉及热点概念事项； （3）近期公司经营情况及内外部经营环境是否或预计将要发生重大变化； （4）公司、控股股东和实际控制人是否存在关于本公司的应披露而未披露的重大事项， 或处于筹划阶段的重大事项； （5）是否存在其他可能对股价产生较大影响的重大事件。 2、 核实对象： 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 2 个有成交的交易日（2024 年 10 月 28 日至 2024 年 10 月 29 日）以内收 盘价涨幅偏离值累计达到 50.85%，根据《北京证券交易所交易规则（试行）》的有关规定， 属于股票交易异常波动情形。 二、公司关注并核实的相关情况 1、 关注问题： （1）前期公告的事项是否取得重大进展或变化，前期披露的公告是否需要更正、补充； ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][3] Core Views - The company achieved a revenue of 436 million yuan in Q1-Q3 2024, representing a year-on-year increase of 19.3%, and a net profit attributable to shareholders of 62.06 million yuan, up 15.5% year-on-year. The non-recurring net profit saw a significant increase of 65.2% [3] - The company is transitioning from a raw material manufacturer to an application service provider, focusing on technological research and development to provide solutions and products for clients. The strategic direction for the next five years includes expanding applications in konjac powder and downstream product processing, particularly in jelly, meat products, tea drink ingredients, and konjac food [4] - The company is actively expanding its customer base, with stable orders from leading enterprises such as Mixue Ice City and Hou Shang Ayi, while also targeting second-tier brand clients. The production capacity is being increased to meet market demand, with a current full-load operation of production lines [5] Financial Summary - For the fiscal years 2022 to 2026, the company forecasts revenue growth from 447 million yuan in 2022 to 688 million yuan in 2026, with corresponding net profits expected to rise from 65 million yuan to 79 million yuan. The projected EPS for these years is 0.89, 0.72, 0.88, 0.97, and 1.07 yuan per share respectively [6][8] - The gross margin is expected to improve slightly from 21.0% in 2023 to 21.9% in 2024, while the net margin is projected to stabilize around 11.5% by 2026 [6][9]

Group 1 - The core viewpoint of the article indicates that the overall decline in the basic chemical industry is 0.28%, with 186 stocks experiencing price increases and 3 stocks, including Yabong Co. and Yayun Co., hitting the daily limit up [1] - Among the stocks that declined, Hanwei Technology, Meibang Technology, and Beihua Co. had significant drops of 10.00%, 8.96%, and 7.75% respectively [1] - The latest margin trading data shows that the margin balance for the stock as of October 25 is 961,100 yuan, with a financing balance of 961,100 yuan, reflecting a decrease of 225,400 yuan over the past 10 days, which is a 19.00% decline [1]

证券代码：839273 证券简称：一致魔芋 公告编号：2024-095 湖北一致魔芋生物科技股份有限公司 关于拟注销控股子公司的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 湖北一致魔芋生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开了第三届董事会第十八次会议、第三届监事会第十七次会议，审议通过 了《关于拟注销控股子公司的议案》。根据公司章程及相关法律法规规定，本议 案无须提交股东大会审议。现将具体情况公告如下： 一、拟注销控股子公司的基本情况 住所：中国(湖北)自贸区宜昌片区生物产业园花溪路 188 号跨境电商产业园 0415 经营范围：生物制品研制、开发、销售；母婴用品、纸尿裤、化妆品、纸制 日用百货的批发、零售；货物进出口贸易（法律、行政法规禁止、限制以及指定 经营的进出口项目除外)；电子商务信息咨询；企业形象策划；会务服务；展览 展示服务；市场调研（服务类，不含社会及民意调查）（依法须经批准的项目， 经相关部门批准后方可开展经营活动） 股东结构：公司持有 ...

证券代码：839273 证券简称：一致魔芋 公告编号：2024-096 湖北一致魔芋生物科技股份有限公司 关于调整公司组织架构的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 湖北一致魔芋生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开了第三届董事会第十八次会议，审议通过了《关于调整公司组织架构的 议案》。根据公司章程及相关法律法规规定，本议案无须提交股东大会审议。现 将具体情况公告如下： 一、公司组织架构调整的情况 股子公司湖北致心生物科技有限公司在完成注销程序后，即从公司组织架构中删 除，公司组织架构不再另行公告。 二、组织架构调整对公司的影响 本次组织架构的调整结合了公司实际发展情况，明晰并强化了各部门的职责 工作，有利于进一步提高组织运营效率。公司的经营主体、经营业务以及人员未 发生重大实质变化，不会影响公司的正常经营，亦不会损害公司及股东的利益。 三、备查文件 1、《湖北一致魔芋生物科技股份有限公司第三届董事会第十八次会议决 议》； 湖北一致魔芋生物科技股 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：839273 证券简称：一致魔芋 公告编号：2024-092 湖北一致魔芋生物科技股份有限公司 第三届董事会第十八次会议决议公告 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 24 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2024 年 10 月 19 日以通讯方式发出 5.会议主持人：董事长吴平女士 6.会议列席人员：公司监事及部分高级管理人员 7.召开情况合法、合规、合章程性说明： （一）审议通过《关于公司<2024 年第三季度报告>的议案》 1.议案内容： 根据《公司法》《证券法》《北京证券交易所上市规则（试行）》等法律法规 及《公司章程》有关规定，公司已编制完成《2024 年第三季度报告》。 具体内容请详见公司于 2024 年 10 月 25 日在北京证券交易所信息披露平台 （https://www.bse.cn）披露的《湖北一致魔芋生物科技 ...

证券代码：839273 证券简称：一致魔芋 公告编号：2024-097 湖北一致魔芋生物科技股份有限公司舆情管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 本制度经公司 2024 年 10 月 24 日第三届董事会第十八次会议审议通过，表 决结果：同意 9 票；反对 0 票；弃权 0 票。本议案无需提交公司股东大会审议 二、 制度的主要内容，分章节列示： 湖北一致魔芋生物科技股份有限公司 舆情管理制度 第一章 总则 第一条 为了提高湖北一致魔芋生物科技股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对 公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益 ，根据相关法律法规的规定和《公司章程》，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造 ...

Financial Performance - Operating revenue for the first nine months of 2024 reached CNY 436,008,784.87, a 19.30% increase from CNY 365,457,658.61 in the same period of 2023[3] - Net profit attributable to shareholders for the first nine months of 2024 was CNY 62,057,856.33, reflecting a 15.51% increase from CNY 53,724,845.77 in the previous year[3] - The net profit after deducting non-recurring gains and losses surged by 65.17% to CNY 57,505,552.90 compared to CNY 34,815,380.83 in the same period last year[3] - In Q3 2024, operating revenue was CNY 174,113,536.13, marking a 28.11% increase from CNY 135,912,587.69 in Q3 2023[3] - Net profit attributable to shareholders in Q3 2024 reached CNY 28,791,286.56, a substantial increase of 71.36% from CNY 16,801,659.39 in Q3 2023[3] - The company reported a basic earnings per share of CNY 0.86 for the first nine months of 2024, up 17.81% from CNY 0.73 in the same period last year[3] - Total operating revenue for the first nine months of 2024 reached ¥436,008,784.87, an increase from ¥365,457,658.61 in the same period of 2023, representing a growth of approximately 19.3%[25] - Net profit for the first nine months of 2024 was ¥60,295,253.15, compared to ¥52,240,738.91 in 2023, reflecting a growth of about 15.5%[28] - The company reported a total profit of ¥72,019,521.61 for the first nine months of 2024, up from ¥59,555,274.09 in 2023, which is an increase of approximately 20.9%[27] Assets and Liabilities - Total assets increased by 11.78% to CNY 717,527,063.26 as of September 30, 2024, compared to CNY 641,885,921.84 at the end of 2023[3] - The asset-liability ratio for the consolidated entity increased to 17.46% from 11.84% year-on-year[3] - The total liabilities increased to CNY 125,308,943.07 from CNY 76,020,669.83, marking a rise of about 65%[20] - The company’s total equity as of September 30, 2024, was CNY 592,218,119.19, compared to CNY 565,865,251.49 at the end of 2023, showing an increase of approximately 4.6%[20] - The total number of unrestricted shares increased from 26,865,750 to 32,868,250, representing a 22.3% increase[8] - The total number of restricted shares decreased from 46,888,250 to 40,885,750, a reduction of 12.8%[8] - The total share capital remains at 73,754,000 shares[8] - Major shareholders include Wu Ping with 19,440,000 shares (26.36%) and Li Li with 10,400,000 shares (14.10%) [9] Cash Flow - Cash flow from operating activities showed a significant decline of 65.66%, totaling CNY 43,168,736.74, down from CNY 125,699,390.32 in the previous year[3] - Operating cash inflow for the first nine months of 2024 was CNY 483,691,774.38, compared to CNY 406,931,621.87 in the same period of 2023, representing an increase of approximately 18.9%[29] - Net cash flow from operating activities for the first nine months of 2024 was CNY 43,168,736.74, a decrease from CNY 125,699,390.32 in the same period of 2023[29] - Total cash inflow from investment activities for the first nine months of 2024 was CNY 1,297,108,203.38, significantly higher than CNY 359,799,868.74 in the same period of 2023[30] - Cash inflow from sales of goods and services for the first nine months of 2024 was CNY 456,643,639.49, up from CNY 377,057,648.88 in the same period of 2023, marking an increase of about 21.0%[29] - Total cash outflow from operating activities for the first nine months of 2024 was CNY 440,523,037.64, compared to CNY 281,232,231.55 in the same period of 2023, indicating a significant increase[29] Research and Development - Research and development expenses increased to ¥16,649,015.77 from ¥13,774,677.84, reflecting a rise of approximately 21.5%[25] - Research and development expenses for the first nine months of 2024 were ¥13,774,278.42, compared to ¥12,052,678.12 in 2023, reflecting an increase of about 14.3%[27] Incentive Plans and Shareholder Matters - The company has implemented an employee incentive plan, which has been approved by the shareholders' meeting[13] - The company approved the 2024 equity incentive plan, including the list of core employees and the first grant of incentive objects, during the board meeting on September 11, 2024[16] - The company did not receive any objections from employees regarding the proposed incentive plan during the public notice period from September 13 to September 22, 2024[16] Other Financial Information - The company incurred credit impairment losses of ¥-310,586.06 in the first nine months of 2024, a significant improvement from ¥-1,111,742.83 in the same period of 2023[26] - The company reported an asset impairment loss of ¥9,484,522.78 in the first nine months of 2024, compared to ¥226,398.74 in the same period of 2023, indicating a significant increase in impairment losses[26] - The company achieved other income of ¥2,895,698.53 in the first nine months of 2024, down from ¥13,702,902.28 in the same period of 2023, indicating a decrease of approximately 78.8%[27] - The company reported a net profit margin improvement, with net income figures to be detailed in future guidance[25] - There are no significant litigation or arbitration matters reported during the period[14]

证券代码：839273 证券简称：一致魔芋 公告编号：2024-094 湖北一致魔芋生物科技股份有限公司 第三届监事会第十七次会议决议公告 根据《公司法》《证券法》《北京证券交易所上市规则（试行）》等法律法规 及《公司章程》有关规定，公司已编制完成《2024 年第三季度报告》。 1.会议召开时间：2024 年 10 月 24 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2024 年 10 月 19 日以通讯方式发出 5.会议主持人：监事会主席万静女士 6.召开情况合法、合规、合章程性说明： 具体内容请详见公司于 2024 年 10 月 25 日在北京证券交易所信息披露平台 （https://www.bse.cn）披露的《湖北一致魔芋生物科技股份有限公司 2024 年 第三季度报告》（公告编号：2024-093）。 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议程序符合《公司法》及《公司章程》的有关 ...